September 2024 in “Journal of the European Academy of Dermatology and Venereology” This study found that baricitinib significantly reduced hair loss in patients with severe alopecia areata, decreasing the mean SALT score from 96.6 to 48 over 24 weeks, with no patients dropping out and only mild adverse events in 12.7% of participants.
8 citations
,
August 2024 in “Clinical and Experimental Dermatology” This review discusses the limitations of existing clinician-reported outcome measures for alopecia areata and emphasizes the need for a composite scoring system to better assess disease severity.
June 2024 in “Dermatology and Therapy” In this study, patients with alopecia areata who experienced sustained hair regrowth while being treated with baricitinib showed improvements in health-related quality of life and reductions in anxiety and depression symptoms over 104 weeks, according to the BRAVE-AA phase III trials.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.
2 citations
,
October 2023 in “Dermatology and therapy” This study conducted in Europe found that both physicians and patients generally agreed on the severity of alopecia areata, with higher physician-rated severity linked to increased patient-reported burdens such as anxiety, depression, and work impairment.
49 citations
,
October 2023 in “Journal of Dermatological Science” 
September 2023 in “Dermatology and Therapy” In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.
September 2023 in “British Journal of Dermatology” In this study, researchers identified subgroups of patients with severe alopecia areata treated with baricitinib who experienced early, gradual, or late hair regrowth, finding that response was influenced by baseline disease severity and duration of hair loss.
3 citations
,
June 2023 in “Journal of dermatological treatment” This study found that patients with severe alopecia areata who experienced meaningful scalp hair regrowth showed greater improvements in health-related quality of life and reduced anxiety and depression compared to those with no or minimal regrowth.
6 citations
,
May 2023 in “Drugs” This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.
20 citations
,
February 2023 in “American Journal of Clinical Dermatology” In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.
148 citations
,
March 2022 in “The New England Journal of Medicine” In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
47 citations
,
December 2020 in “Journal of the European Academy of Dermatology and Venereology” This article reviews the classification, diagnosis, and management of hair disorders, emphasizing the role of trichoscopy and early diagnosis for effective treatment but reports no new clinical findings.
37 citations
,
December 2019 in “Giornale italiano di dermatologia e venereologia” This Italian guideline discusses the diagnosis and treatment of alopecia areata but reports no new clinical trial results; the authors highlight the need for well-designed studies.
